Results 151 to 160 of about 76,991 (209)

Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids. [PDF]

J Med Chem
Chou PY, Lai MJ, Tsai KK, Cheng LH, Wu YW, Chen MC, Pan SL, Ho HO, Nepali K, Liou JP.   +9 more
europepmc   +1 more source

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF^V600E lung adenocarcinoma. [PDF]

Cell Rep Med
Nokin MJ, Darbo E, Richard E, San José S, de Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Jänne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaría D, Bolero Consortium.   +29 more
europepmc   +1 more source

Emerging Neuroprotective Strategies: Unraveling the Potential of HDAC Inhibitors in Traumatic Brain Injury Management. [PDF]

Curr Neuropharmacol
Ye L, Li W, Tang X, Xu T, Wang G.
europepmc   +1 more source

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization. [PDF]

ACS Chem Biol
Bauer N, Balourdas DI, Schneider JR, Zhang X, Berger LM, Berger BT, Schwalm MP, Klopp NA, Siveke JT, Knapp S, Joerger AC.   +10 more
europepmc   +1 more source

Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells. [PDF]

Iran J Basic Med Sci
Wang L, Xu Y, Gao C.
europepmc   +1 more source

HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer. [PDF]

Int J Oncol
He Y, Ma Y, Zhu Y, Zhang J, Zhao S, Zhang D, Xu D, Li Y, Tong Z, Zhao W.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

NO-HDAC dual inhibitors

European Journal of Medicinal Chemistry, 2022
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis ...
Negar, Omidkhah, Razieh, Ghodsi
openaire   +2 more sources